CI24-10034
|
Improving taxol response through the manipulation of the cancer tubulin code
|
Sonia Silva
|
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação
|
Consortium
|
Universidade do Porto
|
STAGE 1
|
Therapeutics
|
49,967,00
|
CI24-10180
|
Molecular glue degraders for a novel drug target in acute myeloid leukemia
|
Marcus Buschbeck
|
Fundació Institut de Recerca Contra la Leucèmia Josep Carreras
|
Individual
|
N/A
|
STAGE 1
|
Therapeutics
|
49,000,00
|
CI24-10227
|
Generating tissue resident memory T cells for cancer immunotherapy
|
Marc Veldhoen
|
Instituto de Medicina Molecular
|
Individual
|
N/A
|
STAGE 1
|
Therapeutics
|
50,000,00
|
CI24-10473
|
Chemical inhibition of novel Diffuse Midline Glioma vulnerabilities
|
Luciano Di Croce
|
Fundació Centre de Regulació Genòmica (CRG)
|
Individual
|
N/A
|
STAGE 1
|
Therapeutics
|
50,000,00
|
CI24-10612
|
Targeting cryptic exons as biomarkers and ALS therapy
|
Manuel Portero
|
Institut De Recerca Biomedica De Lleida. Fundació Dr. Pifarre
|
Individual
|
N/A
|
STAGE 1
|
Therapeutics
|
41,000,00
|
CI24-10630
|
Non-opioid light-activated drugs for pain management without side effects
|
Amadeu Llebaria
|
Consejo Superior de Investigaciones Científicas (CSIC)
|
Consortium
|
Institut de Génomique Fonctionnelle (France); University of Montpellier (France)
|
STAGE 1
|
Therapeutics
|
50,000,00
|
CI24-10110
|
Genetic predisposition to myocardial infarction in the young
|
Ramon Brugada
|
Institut d'Investigació Biomèdica de Girona (IDIBGI)
|
Individual
|
N/A
|
STAGE 1
|
Diagnostics
|
49,000,00
|
CI24-10322
|
CELLECTED - An Innovative Approach for Non-Invasive Bladder Cancer Detection and Patient Monitoring
|
Raphaël Canadas
|
Universidade do Porto
|
Individual
|
N/A
|
STAGE 1
|
Diagnostics
|
49,999,00
|
CI24-10486
|
MSPredict: MS Prognosis through Advanced Imaging Analysis
|
Pablo Naval
|
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
|
Individual
|
N/A
|
STAGE 1
|
Medical Devices
|
50,000,00
|
CI24-10491
|
An aptamer-based rapid diagnostic test for the simultaneous detection of malaria and dengue
|
Claudio Parolo
|
Institut de Salut Global de Barcelona (ISGlobal)
|
Consortium
|
FURV-Fundació Universitat Rovira i Virgili
|
STAGE 1
|
Diagnostics
|
50,000,00
|
CI24-10670
|
Validation of a new methodology and biomarkers for predicting relapse in endometrial cancer patients
|
Maria J. Macias
|
Fundació Institut de Recerca Biomèdica (IRB Barcelona)
|
Individual
|
N/A
|
STAGE 1
|
Diagnostics
|
50,000,00
|
CI24-10681
|
Leveraging Genomics and AI for Non-Invasive Detection of Endometrial Cancer, a Urine Sample Solution
|
Laura Costas
|
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
|
Individual
|
N/A
|
STAGE 1
|
Diagnostics
|
50,000,00
|
CI24-10743
|
Artificial Intelligence system for predicting embolisms in infective endocarditis
|
J. Alberto San Román
|
Hospital Clínico Universitario de Valladolid
|
Individual
|
N/A
|
STAGE 1
|
Diagnostics
|
50,000,00
|
CI24-10063
|
Biomimetic Bacterial NanoCellulose medical device with gradient porosity for osteochondral repair
|
Miguel Gama
|
Universidade do Minho
|
Consortium
|
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação; Universidade de Trás-os-Montes e Alto Douro
|
STAGE 1
|
Medical Devices
|
50,000,00
|
CI24-10305
|
Focused ultrasound therapy for repairing spinal cord in people with Multiple Sclerosis (MS)
|
Pablo Villoslada
|
Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)
|
Individual
|
N/A
|
STAGE 1
|
Medical Devices
|
50,000,00
|
CI24-10293
|
Hereditary Diffuse Gastric Cancer origins disclosed by organoid driven organ-on-chip technology
|
Daniel A. Ferreira
|
i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação
|
Individual
|
N/A
|
STAGE 1
|
Diagnostics
|
49,000,00
|
CI24-20222
|
NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease
|
Julia Lorenzo
|
Universitat Autònoma de Barcelona (UAB)
|
Consortium
|
Fundación de la Comunidad Valenciana Centro de Investigación Príncipe Felipe; Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
|
STAGE 2
|
Therapeutics
|
150,000,00
|
CI24-20449
|
Testing targeted drug therapy in metabolic liver disease
|
Cecilia Rodrigues
|
FARM-ID - Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento
|
Individual
|
N/A
|
STAGE 2
|
Therapeutics
|
150,000,00
|
CI24-20467
|
Development of a microRNA-regulated cell death-inducing gene therapy (miRGT) for cancer
|
Ana Rita Fragoso
|
Instituto de Medicina Molecular
|
Individual
|
N/A
|
STAGE 2
|
Therapeutics
|
149,032,50
|
CI24-20581
|
Towards an effective and safe therapy for hormonal-deficiency osteoporosis based on klotho protein
|
Joan Roig
|
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
|
Consortium
|
Universitat Autònoma de Barcelona (UAB)
|
STAGE 2
|
Therapeutics
|
145,850,00
|
CI24-20693
|
Targeting CDK16-18 as a novel strategy against aggressive cancers
|
Marcos Malumbres
|
Fundació privada Institut Investigació Oncologica Vall d'Hebron (VHIO)
|
Individual
|
N/A
|
STAGE 2
|
Therapeutics
|
150,000,00
|
CI24-20107
|
A medical brain computer interface device to improve social cognition in autism spectrum disorder
|
Miguel Castelo-Branco
|
Universidade de Coimbra
|
Individual
|
N/A
|
STAGE 2
|
Medical Devices
|
148,980,19
|
CI24-20130
|
Artificial intelligence collaborative robot for patient-specific laser treatment of vascular lesions
|
Bruno Oliveira
|
Instituto Politécnico do Cávado e do Ave
|
Consortium
|
University of Southern Denmark (Dinamarca)
|
STAGE 2
|
Medical Devices
|
150,000,00
|
CI24-20329
|
Famba: international surveillance and data analytics platform for prevention of emerging pandemics
|
José Muñoz
|
Institut de Salut Global de Barcelona (ISGlobal)
|
Consortium
|
Institute of Tropical Medicine, Antwerp (Belgium); LMU Klinikum (Germany); IRCCS Ospedale Sacro-Cuore Don Calabria (Italy)
|
STAGE 2
|
Digital Health
|
149,930,00
|
CI24-20447
|
CRISPR-Cas Endonuclease Chain Reaction: a revolution in point-of-care genetic testing
|
Felipe Cortés
|
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III
|
Individual
|
N/A
|
STAGE 2
|
Diagnostics
|
150,000,00
|
CI24-20499
|
NeurAntigen: A Human Neural Method for the Diagnosis of Autoimmune Encephalitis
|
Eugenia Martínez Hernández
|
Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer
|
Consortium
|
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
|
STAGE 2
|
Diagnostics
|
150,000,00
|
CI24-20039
|
Antimicrobial bioinspired membranes for skin regeneration
|
Salvio Suárez
|
Fundació Institut Català de Nanociència i Nanotecnologia
|
Individual
|
N/A
|
STAGE 2
|
Medical Devices
|
150,000,00
|
CI24-30620
|
Heptammune: a first-in-class biologic immunomodulator against autoimmune inflammatory bowel disease
|
Josep M. Aran
|
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
|
Individual
|
N/A
|
STAGE 3
|
Therapeutics
|
500,000,00
|
CI24-30165
|
SureVision
|
Víctor Rodriguez
|
Consejo Superior de Investigaciones Científicas (CSIC)
|
Individual
|
N/A
|
STAGE 3
|
Medical Devices
|
499,000,00
|